Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
39 hedge funds and large institutions have $84.1M invested in Biora Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 10 closing their positions.
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
44% more funds holding
Funds holding: 27 → 39 (+12)
0% less capital invested
Capital invested by funds: $84.5M → $84.1M (-$375K)
0.75% less ownership
Funds ownership: 20.79% → 20.04% (-0.75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.62M |
| 2 |
BlackRock
New York
|
+$905K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$498K |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$452K |
| 5 |
DCM
Dupont Capital Management
Wilmington,
Delaware
|
+$339K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$2.15M |
| 2 |
HP
Hound Partners
New York
|
-$1.99M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$900K |
| 4 |
ZP
Zimmer Partners
New York
|
-$900K |
| 5 |
Goldman Sachs
New York
|
-$576K |
BIOR Hedge Fund Activity: Q3 2020 in Review
39 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q3 2020, worth a combined $84.1M — down 0.44% from $84.5M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new BIOR positions and 10 closed out — a net gain of 12 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.62M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $2.15M sold.
- 39 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q3 2020, up from 27 in Q2 2020.
- Funds reported $84.1M of Biora Therapeutics, Inc. Common Stock stock for Q3 2020, down 0.44% quarter-over-quarter.
- 22 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q3 2020 and 10 closed out, a net change of +12 holders.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q3 2020 was Armistice Capital, an estimated $3.62M added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q3 2020 was Avidity Partners Management, an estimated $2.15M sold.
Based on aggregated 13F filings for Q3 2020.